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ABSTRACT
Background. Acute myocardial infarction is associated with a local and systemic inflammatory response 
which may result in the healing of necrotic myocardium to preserve left ventricular systolic function (LVSF). 
Aim. To assess the course of inflammatory activation during hospitalisation and at one month after discharge 
in patients with preserved global LVSF in six month follow-up after a first acute ST-elevation myocardial 
infarction (STEMI), treated with primary percutaneous coronary intervention (pPCI). 
Material and methods. The study group consisted of 199 patients with STEMI treated with pPCI. The fol-
lowing LVSF echocardiographic parameters were assessed before hospital discharge and at six months 
after STEMI: left ventricular ejection fraction, wall motion score index and average peak systolic mitral 
annular velocity. C-reactive protein (CRP) plasma concentrations were measured with an ultra-sensitive 
latex immunoassay on admission, 24 hours after admission, at discharge and one month after STEMI. 
Results. Preserved global LVSF (LVEF > 50%) was present in 24.0% of patients at discharge and in 
35.2% of patients at six months after STEMI (p < 0.001). Plasma CRP concentration steeply rose in study 
participants during the first 24 h of hospitalisation (p < 0.001) and persisted elevated at discharge. CRP 
concentrations 24 h after admission, at discharge and at one month after STEMI were lower in patients with 
preserved global LVSF at six month follow-up compared to patients with LVEF ≤ 50%. Normalisation of CRP 
concentration after one month occurred exclusively in patients with preserved LVSF at six months. Patients 
with preserved global LVSF at six months had a lower prevalence of anterior STEMI, diabetes mellitus and 
symptomatic heart failure at discharge, lower body mass index, more favourable pre-pPCI angiographic 
flow indices, better final angiographic outcome of pPCI with complete microvascular reperfusion in 57.1% 
of cases, lower values of myocardial necrosis indices, admission glycaemia, glycated haemoglobin, B-type 
natriuretic peptide plasma concentration; lower left ventricular volumes and mass and less impaired 
regional and longitudinal LVSF both at discharge and after six months than patients without preserved 
global LVSF at six months after STEMI. 
Conclusions. Patients with preserved global LVSF at six months after a first STEMI treated with pPCI have 
a lower intensity of inflammatory response, as assessed by plasma CRP concentration measured during 
the acute phase, than patients presenting with LVEF ≤ 50% at six month follow-up. 
Key words: acute myocardial infarction, left ventricular systolic function, echocardiography, C-reactive 
protein, inflammation
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Introduction
Acute myocardial infarction is associated with a local 
and systemic inflammatory response [1–3]. The inflam-
matory activation may result in the healing of necrotic 
myocardium to preserve left ventricular (LV) function, 
but there is experimental evidence that, when exagger-
ated, it might also promote tissue injury [3]. Decreased 
myocardial perfusion results in augmented production 
of non-specific plasma acute-phase proteins, including 
C-reactive protein (CRP) [4–8]. In experimental models, 
the concentration of inflammatory mediators increases 
in the course of acute myocardial necrosis in the initial 
hours since the onset of symptoms [3]. The tissue inflam-
matory response is not limited to the area of necrosis, but 
extends to the intact portions of myocardium [3, 4, 6, 7]. 
The cytokines released in the process of myocardial 
damage influence the expansion of necrosis and scar 
formation by affecting cell growth and migration as 
well as the repair processes [3]. These mediators also 
stimulate CRP expression [9, 3, 10]. Literature data also 
suggests that apart from being an inflammatory marker, 
CRP should also be regarded as an inflammatory media-
tor holding pro-thrombotic and pro-apoptotic properties 
[10–14]. As reported in several studies, elevated CRP 
levels after acute myocardial infarction are associated 
with adverse clinical outcomes, including cardiac rup-
ture, LV dysfunction and remodelling, heart failure (HF) 
and cardiac death, both at hospital discharge and in 
long-term follow-up [1, 15–24]. 
Based upon the literature, the prevalence of pre-
served LV systolic function (LVSF) in post–myocardial 
infarction patients is estimated to range between 40% 
and 73%, depending on applied diagnostic criteria 
(most commonly left ventricular ejection fraction 
[LVEF]), therapeutic approach and time point of assess-
ment [25–29]. Quick implementation of primary percu-
taneous coronary intervention (pPCI) with concomitant 
complete reperfusion in the ischaemic area in the setting 
of acute ST-elevation myocardial infarction (STEMI) 
should reduce the area of necrosis and promote the 
preservation of LVSF [30–33]. Effective reperfusion ther-
apy may modify the course of inflammatory activation 
during acute myocardial infarction [18, 34–36]. 
The potential effect of plasma CRP concentration 
on LV structure and function in patients after acute first 
STEMI warrants further investigation. While well doc-
umented for populations with post-infarct LV systolic 
dysfunction (LVSD), there is limited data regarding 
the course of inflammatory activation during acute 
myocardial infarction in patients with preserved LVSF 
in long-term follow-up [21, 37–40]. 
We therefore set out to assess the course of inflam-
matory activation during hospitalisation and at one month 
after discharge in patients with preserved global LVSF in 
six month follow-up after a first STEMI, treated with pPCI. 
Material and methods
Study design and patient characteristics
This study was designed as a single-centre prospec-
tive observational cohort trial in the setting of first STEMI 
treated with pPCI, with consecutive patients enrolled in 
the Department of Cardiology and Internal Medicine of 
Antoni Jurasz University Hospital in Bydgoszcz between 
25 November 2005 and 27 November 2008 [41]. The 
inclusion criteria were: 
 — typical stenocardial chest pain of at least 30 minutes’ 
duration;
 — onset of symptoms < 12 h before hospital admission;
 — electrocardiographic features of acute STEMI 
(ST-segment elevation  ≥0.1 mV or ≥ 0.2 mV in at 
least two contiguous limbs or precordial leads, 
respectively). 
The exclusion criteria included: 
 — prior coronary revascularisation;
 — cardiogenic shock on admission;
 — severe heart failure (New York Heart Association 
class III or IV);
 — bundle branch block;
 — permanent atrial fibrillation; 
 — haemodynamically significant valvular heart disease;
 — primary cardiomyopathy;
 — severe arterial hypertension;
 — creatinine concentration > 176.8 mmol/L;
 — presence of features suggestive of an active inflam-
matory process on admission;
 — therapy with steroids, immunosuppressive agents 
and non-steroidal anti-inflammatory drugs (exclud-
ing low doses of aspirin). Diagnosis of diabetes 
mellitus (DM) was established based on a positive 
result of oral glucose tolerance test performed on 
day 3 of hospitalisation or if the patient had been 
receiving antidiabetic treatment (with oral hypogly-
caemic drugs or insulin) [42]. 
Approval from The Local Bioethics Committee at 
Collegium Medicum in Bydgoszcz was obtained. All 
patients gave their written, voluntary, informed consent 
for participation in the study.
Pharmacotherapy
At first contact with healthcare providers, imme-
diately after establishing the diagnosis of STEMI, all 
patients were pre-treated with an intravenous bolus 
of unfractionated heparin (70 IU/kg, up to 5,000 IU) 
and oral loading doses of clopidogrel (600 mg) and 
aspirin (300 mg). At the catheterisation laboratory, 
a second dose of unfractionated heparin was admin-
istered intra-arterially in a weight-adjusted manner (up 
to 100 IU/kg) or under activated clotting time guidance 
(to the target range of 200-250 seconds) when abcix-
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imab was intended. Abciximab was given at the discre-
tion of the invasive cardiologist. Diabetic patients with 
admission glycaemia ≥ 7.8 mmol/L and those without 
diabetes with glycaemia of ≥ 10.0 mmol/L on admission 
were put on short-acting insulin infusion for the first 
24 hours of hospitalisation to maintain glucose levels 
between 7.8 and 10.0 mmol/L [42]. Starting from the 
second day of hospitalisation, patients with glycaemia 
levels > 10.0 mmol/L on blood glucose profile received 
intensive insulin therapy until discharge from hospital, 
with subsequent therapy with pre-mixed insulin for three 
months following STEMI [43]. Throughout the study pe-
riod, clopidogrel and aspirin 75 mg q.d. were continued 
in all patients. Concomitant medications in the majority 
of patients included perindopril and long-acting metop-
rolol in doses adjusted for resting heart rate and blood 
pressure, and simvastatin 40 mg q.d.. Spironolactone 
and non-potassium-sparing diuretics were given at the 
discretion of the cardiologist.
Coronarography and primary percutaneous 
coronary intervention 
Coronarography and pPCI were performed using 
a standard femoral or radial approach. The use of 
aspiration thrombectomy during the intervention was 
left to the operator’s discretion. Intracoronary stents 
were routinely implanted. Coronary artery stenosis was 
measured with QCA (quantitative coronary angiogra-
phy). Epicardial coronary flow was assessed according 
to the TIMI (Thrombolysis in Myocardial Infarction) 
score and TFC (TIMI frame count), and myocardial 
perfusion according to the TMPG (TIMI Myocardial 
Perfusion Grade).
Echocardiography 
Transthoracic echocardiographic recordings em-
ploying the Doppler technique were acquired at hospital 
discharge (D) and six months (M6) after STEMI using 
a Philips SONOS 7500 Ultrasound System, in accordance 
to the protocol recommended by the American Society of 
Echocardiography, the European Association of Echo-
cardiography and the Polish Cardiac Society [44–46]. 
Echocardiographic recordings were assessed offline 
twice by an experienced echocardiographer blinded 
to biomarker measurement results. Measurements are 
reported as an average of three consecutive cardiac 
cycles. The intra-observer coefficients of variation for 
LVEF assessed in first 50 patients were below 2.5%.
Diameter, volume and mass indices
The following indices were measured: left atrial 
end-systolic diameter (LA); LV end-diastolic diameter 
(LVEDd); LV end-diastolic diameter index (LVEDdI); LV 
end-diastolic volume (LVEDV); LV end-diastolic volume 
index (LVEDVI); LV end-systolic diameter (LVESd); 
LV end-systolic diameter index (LVESd); LV end-systolic 
volume (LVESV); and LV end-systolic volume index 
(LVESVI). LV mass index (LVMI) was calculated ac-
cording to the Devereux formula [45]. LV hypertrophy 
was diagnosed when the value of LVMI was above 
117.0 g/m2 in men and 101.0 g/m2 in women [45].
Left ventricular systolic function
LVEF, a marker of global LVSF, was calculated us-
ing the modified Simpson rule [45]. Wall motion score 
index (WMSI), reflecting regional LVSF, was derived as 
a sum of all scores divided by the number of segments 
visualised, implementing the 16-segment model of 
LV segmentation and assigning a score from 1 point 
(normal) to 4 points (dyskinesia), respectively [45]. 
Measurements of peak mitral annular velocities were 
obtained for four basal segments of LV (septal, later-
al, inferior and anterior) using pulsed tissue Doppler 
echocardiography with the Doppler gate targeted at 
the junction of LV walls with the mitral annulus in four- 
and two-chamber views. Average peak systolic mitral 
annular velocity (S¢) and average septal and lateral 
peak systolic mitral annular velocity (S”), the markers 
of longitudinal LVSF, were obtained [47]. LVSF was 
classified as follows: 
 — global — according to the value of LVEF: > 50% 
— as preserved; ≤ 50% and > 40% — as moderate 
LVSD; ≤ 40% — as significant LVSD; ≤ 30% — as 
severe LVSD; 
 — regional — according to the value of WMSI: 
< 1.3 — as preserved; ≥ 1.3 and < 1.7 — as mod-
erate LVSD; ≥ 1.7 — as significant LVSD;
 — longitudinal — according to the value of S’: > 7.5 cm/s 
— as preserved; ≤ 7.5 cm/s and > 6.0 cm/s — as 
moderate LVSD; ≤ 6.0 cm/s — as significant LVSD 
[41, 46, 47]. 
 — As a next step, patients were divided according to 
the values of LVEF at six months after discharge into 
two groups: the first group with preserved global 
LVSF — LVEF > 50% (signified as PLVSF M6+), 
and the second group without preserved global 
LVSF — LVEF ≤ 50% (signified as PLVSF M6–).
Left ventricular diastolic function
Diastolic LV function was assessed using pulsed 
Doppler echocardiography and pulsed tissue Doppler 
echocardiography by measurements of peak velocity 
transmitral flow in the early phase (E) and during atrial 
systole (A) to obtain the E/A ratio, deceleration time of 
early transmitral flow (DT), isovolumic relaxation time 
(IVRT), reverse pulmonary vein flow (rAv) and the E/E’ 
ratio, where E’ is the average peak early diastolic mitral 
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annular velocity [47]. LV diastolic dysfunction was clas-
sified as [48]: mild — E/A < 0.8; DT > 200 ms; E/E’ ≤ 8; 
moderate — E/A 0.8–1.5; DT 160–200 ms; E/E’ 9–12 or 
severe — E/A ≥ 2; DT < 160 ms; E/E’ ≥ 13.
Blood sampling and laboratory analyses
Routine in-hospital laboratory analyses, performed 
in each case of acute STEMI in the Department of Cardi-
ology and Internal Medicine of Antoni Jurasz University 
Hospital in Bydgoszcz, are presented in Table 1. Addi-
tional biochemical measurements included troponin I 
(cTnI) concentration 12 and 24 h after admission and 
glycated haemoglobin (HbA1c). 
Biomarkers
Peripheral venous blood samples were collected 
using ethylenediaminetetraacetic acid tubes. Until 
analysed, centrifuged plasma samples were stored at 
–80°C. CRP plasma concentration was measured with 
an ultra-sensitive latex immunoassay (CRP Vario test, 
analyser: ARCHITECT ci 8200, ABBOTT, Wiesbaden, 
Germany) on admission (CRPa), 24 h after admission 
(CRP24) and at discharge (CRPd). B-type natriuretic 
peptide (BNP) plasma concentration was evaluated 
with a chemiluminescent microparticle immunoassay 
(analyser: ARCHITECT ci 8200, ABBOTT, Wiesbaden, 
Germany) on admission (BNPa) and at discharge 
(BNPd). The limits of detection for CRP and BNP were 
0.1 mg/L and 10.0 pg/L, respectively. The intra-assay 
coefficients of variation were below 2.0% for CRP and 
below 5.0% for BNP, while the inter-assay coefficients 
of variation were below 1.0% for CRP and below 5.0% 
for BNP, respectively.
Statistical analysis
The statistical analysis was carried out using the 
Statistica 8.0 package. Due to non-normal data distribu-
tion, as assessed with the Shapiro-Wilk W-test and the 
Kolmogorov-Smirnov test, the results are presented as 
median values and IQ ranges for quantitative variables 
and as percentages of the population for qualitative 
parameters. Analysis of the differences between sub-
groups was performed using a non-parametric test (the 
Mann-Whitney U-test or the Kruskal-Wallis ANOVA). 
Wilcoxon’s signed rank test was used to evaluate de-
pendent samples. The c2
 
test (with the Yates correction 
if required) was used for qualitative variables. Two-sided 
differences were considered significant at p < 0.05. 
Results
Patients 
The study group consisted of 199 patients including 
154 men (77.4%) and 45 women (22.6%) with acute 
STEMI treated with pPCI, who attended the follow-up 
visit six months after discharge (Table 2). Preserved 
global LVSF (LVEF > 50%) was present in 24.0% of 
patients at hospital discharge, and in 35.2% of patients 
at six months after STEMI (p < 0.001) (Figure 1). 
Clinical, angiographic and biochemical 
assessment during hospitalisation 
Compared to the PLVSF M6– group, patients with 
preserved global LVSF at six months (PLVSF M6+) 
had a lower prevalence of anterior STEMI and DM 
(Table 2). They also had significantly lower values of 
body mass index (BMI). Symptomatic HF at hospital 
discharge was a significantly more frequent finding 
in patients without preserved LVSF at six-month 
follow-up. Additionally, at hospital discharge only 
patients in the PLVSF M6– group required treatment 
with diuretics.
The PLVSF M6+ group presented with noticeably 
more favourable pre-pPCI angiographic indices of flow 
in the infarct-related artery (IRA) (less frequent occur-
rence of culprit lesion in the left descending artery, pre-
served residual flow in 40.0% of patients) compared to 
the PLVSF M6– group (Table 3). Also, final angiographic 
Table 1. Routine in-hospital laboratory analyses performed during hospitalisation in patients with acute ST-elevation 
myocardial infarction 
Timing Laboratory analyses
On admission CK, CK-MB, cTnI, CBC, BUN, creatinine, jonogram, lipid profile, fibrinogen, aPTT, INR, HBs antigen,  
anti-HCV antibodies, blood group
After 6 h CK, CK-MB, cTnI, morphology, aPTT
After 12 h CK, CK-MB, morphology
After 24 h CK, CK-MB, morphology, BUN, creatinine
At discharge Morphology
CBC — complete blood count; CK — activity of creatine kinase; CK-MB — activity of izoenzyme MB of creatine kinase
10
folia Medica copernicana 2014, vol. 2, no. 1
www.fmc.viamedica.pl
Table 2. Demographic and clinical characteristics of groups of patients:  with (PLVSF M6+ group) and without 
(PLVSF M6– group) preserved global left ventricular systolic function at six months after discharge
Variable PLVSF M6+ group  
(n = 70)
PLVSF M6– group  
(n = 129)
p
PLVSF M6+ vs. 
PLVSF M6–
Age (years) 57.0 (50.0–64.0) 56.0 (50.0–64.0)  NS
Gender (male/female) n (%) 57/13 (81.4/18.6) 97/32(75.2/24.8) NS
Anterior wall STEMI n (%) 10 (14.3) 78 (60.5) < 0.001
Time from symptom onset to balloon inflation [minutes] 195.0 (145.0–312.0) 203.0 (140.0 285.0) NS
BMI [kg/m2] 25.5 (23.4–27.8) 27.5 (24.6–29.4) 0.005
Abdominal circumference [cm] 95.0 (88.0–103.0) 100.0 (93.0–107.0) 0.01 NS
Hypertension n (%) 27 (38.6) 55 (42.6) NS
Diabetes mellitus n (%) 6 (8.6) 31 (24.0) 0.007
Angina preceding STEMI n (%) 27 (38.6) 57 (44.2) NS
Heart failure (NYHA I/II) prior to STEMI n (%) 1 (1.4) 6 (4.7) NS
Current or ex-smoker n (%) 31 (63.3) 103 (66.4) NS
Heart failure (NYHA ≥ II) at discharge n (%) 1 (1.4) 19 (14.7) 0.001
Medical treatment at hospital discharge n (%)
Acetylsalicylic acid  70 (100.0) 129 (100.0) NS
Clopidogrel 70 (100.0) 128 (99.2) NS
Simvastatin 69 (98.6) 129 (100.0) NS
Perindopril 69 (98.6) 129 (100.0) NS
Long-acting metoprolol  70 (100.0) 127 (98.5) NS
Spironolactone 0 (0.0) 15 (11.6) 0.003
Non-potassium-sparing diuretics 0 (0.0) 12 (9.3) 0.008
Figure 1. Prevalence of preserved global left ventricular systolic function and left ventricular systolic dysfunction in study 
population at hospital discharge and six months post-discharge
results of pPCI were better in those with preserved LVSF 
at six-month follow-up, with complete microvascular 
reperfusion in more than half of the cases.
Patients with preserved global LVSF presented with 
significantly lower values of myocardial necrosis indi-
ces, admission glycaemia, HbA1c and white blood cell 
count (WBC) at 24 h after admission (Table 4).
Biomarkers
Admission BNP concentration was higher in 
patients without preserved LVSF after six months, 
compared to the PLVSF M6+ group (Table 4). BNP 
concentration rose during hospitalisation in all patients, 
predominantly in the PLVSF M6– group, so that the 
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Table 3. Angiographic characteristics of groups of patients:  with (PLVSF M6+ group) and without (PLVSF M6– 
group) preserved global left ventricular systolic function at six months after discharge
Variable PLVSF M6+ group 
(n=70)
PLVSF M6– group 
(n=129)
p
PLVSF M6+ vs. PLVSF M6–
Infarct-related artery: LAD/ non-LAD n (%) 15 (21.4)/55 (78.6) 77 (59.7)/52 (40.3) < 0.001
Multivessel coronary artery disease n (%) 38 (54.3) 81 (62.8) NS
Stenosis in QCA (%)
 before pPCI
 after pPCI
91.8 ± 10.7
12.8 ± 12.9
95.3 ± 8.3
11.1 ± 8.2
0.01
NS
Flow in TFC [frames/s]
 before pPCI
 after pPCI
67.6 ± 35.3
22.2 ± 15.4
79.5 ± 31.7
27.8 ± 19.1
0.016
0.036
TIMI flow n (%)
 TIMI 0-1 before pPCI
 TIMI 3 before pPCI
 TIMI 3 after pPCI
35 (50.0)
28 (40.0)
67 (95.7)
87 (67.4)
27 (20.9)
118 (91.5)
0.03
0.03
NS
TMPG 3 after pPCI  n (%) 40 (57.1) 52 (40.3) 0.023
Patients with implanted stents n (%)
Patients with implanted DES n (%)
68 (97.1)
1 (1.4)
129 (100.0)
2 (1.6)
NS
NS
Abciximab use n (%) 12 (17.1) 38 (29.4) 0.05
LAD — left anterior descending artery; DES — drug-eluting stent
Table 4. Biochemical characteristics of groups of patients:  with (PLVSF M6+ group) and without (PLVSF M6– group) 
preserved global left ventricular systolic function at six months after discharge
Variable PLVSF M6+ group (n = 70) PLVSF M6– group (n = 129) p
PLVSF M6+ vs.
 PLVSF M6–  
CK-MBa [U/l] 24.0 (18.0–34.0) 28.0 (18.0–51.0) 0.044
CK-MB24 [U/l] 84.0 (44.5–123.0) 110.0 (64.0–164.0) 0.006
CK-MBmax [U/l] 86.0 (47.5–127.5)  119.0 (68.0–178.0) 0.002
cTnIa [ng/mL] 0.26 (0.05–0.95) 0.28 (0.08–1.18) NS
cTnImax [ng/mL] 24.2 (7.9– > 50.0) > 50.0 (16.8–> 50.0) 0.001
Creatinine [µmol/L]* 79.6 (70.7–93.7) 84.9 (76.0–97.2) NS
Haemoglobin [mmol/L]* 14.5 (13.7–15.3) 14.7 (13.6–15.5) NS
WBCa 10.6 (9.0–12.8) 11.6 (9.1–13.5) NS
WBC24 9.8 (8.2–11.2) 10.4 (8.8–12.3) 0.002
Admission glycaemia [mmol/l] 7.1 (6.4–8.1) 7.9 (6.9–9.7) 0.008
HbA1c [%] 5.9 (5.5–6.4) 6.2 (5.7–6.8) 0.035
TC [mmol/L]* 5.7 (5.0–6.2) 5.8 (5.1–6.6) NS
LDL-C [mmol/l]* 3.8 (3.2–4.3) 3.7 (3.3–4.5) NS
HDL-C [mmol/l]* 1.3 (1.2–1.5) 1.3 (1.2–1.5) NS
TG [mmol/l]* 0.9 (0.7–1.4) 1.1 (0.7–1.7) NS
BNPa [pg/mL] 41.7 (20.0–75.0) 56.9 (30.2–129.2) 0.028
BNPd [pg/mL] 86.5 (56.0–156.2) 152.6 (83.8–299.9) < 0.001
BNPa-d [pg/mL] 42.2 (14.9–81.3) 74.7 (7.5–199.8) 0.004
CRPa [mg/L] 1.93 (0.84–3.3) 1.74 (1.15–3.28) NS
CRP24 [mg/L] 7.55 (4.75–11.7) 13.04 (6.21–23.27) 0.002
CRPd [mg/L] 9.07 (3.89–14.4) 10.44 (5.84–20.68) 0.006 
CRP M1 [mg/L] 1.38 (0.77–3.44) 1.77 (0.97–3.07) 0.045
*on admission
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Figure 2. C-reactive protein plasma concentrations on admission, 24 hours after admission, at hospital discharge, and 
at one month after STEMI in patients with and without preserved global left ventricular systolic function after six months
latter group presented with remarkably higher BNP 
levels at discharge.
At baseline, there were no significant differences in 
CRP concentration between patients with and without 
preserved global LVSF at six months (Table 4, Figure 2). 
Plasma CRP concentration steeply rose during the 
initial 24 h of hospitalisation (p < 0.001), mainly in the 
PLVSF M6– group, and persisted elevated at discharge 
in both groups (Figure 2). CRP concentrations 24 h after 
admission, at discharge and at one month after STEMI 
were significantly lower in patients with preserved global 
LVSF at six month follow-up (Table 4). Additionally, 
normalisation of CRP concentration after one month 
occurred exclusively in patients with preserved LVSF 
at six months.
Echocardiographic assessment at discharge  
and after six months
At baseline, patients with preserved global LVSF 
after six months presented with moderate global and re-
gional LVSD and preserved longitudinal LVSF (Table 5). 
At hospital discharge, the PLVSF M6– group had sig-
nificantly higher values of LV volumes and mass than 
patients with LVEF > 50% at six months. Significantly 
higher WMSI and markedly lower S’ values were ob-
served in the former group, indicating more impaired 
regional and longitudinal LVSF. At baseli ne, there was 
significant regional and moderate global and longitudi-
nal LVSD in the PLVSF M6– group. 
At six month follow–up, we observed an increase in 
left heart chamber sizes, LVMI and LVEF with a concom-
itant decrease in WMSI and S’ in both groups. Finally, 
after six months the PLVSF M6– group had significantly 
larger diameters of LA and LV, higher systolic and dia-
stolic LV volumes, and greater LVM than patients with 
preserved global LVSF. The regional and longitudinal 
LVSF were moderately impaired in both groups, though 
the decline was greater in the PLVSF M6– group than 
in their counterparts with preserved global LVSF after 
six months. Also, the echocardiographic indices of LV 
diastolic function were more abnormal in the PLVSF 
M6– group, though moderate LV diastolic dysfunction 
was noted in both groups. 
Discussion
The present study shows a lower intensity of inflam-
matory response, as assessed by plasma CRP concen-
tration measured during the acute phase of a first STEMI 
treated with pPCI, in patients with preserved global 
LVSF at six months after hospital discharge, compared 
to patients with LVEF ≤ 50% at six month follow-up. The 
results of our study describe the course of inflamma-
tory activation during the acute STEMI in patients with 
preserved LVSF in long-term observation. According to 
our findings, this group of patients is subject to a severe 
early inflammatory reaction as indicated by the dynamic 
changes in CRP concentration, with its steep rise during 
first 24 hours of hospitalisation, persistent elevation until 
hospital discharge and subsequent normalisation within 
one month after STEMI. Patients with LVEF > 50% at 
six-month follow-up however presented with a less 
abrupt, significantly lower and shorter-lasting increase 
in CRP concentration. Additionally, CRP concentration 
normalised after one month only in these patients. Thus, 
CRP concentration at each assessed time point was 
lower in this group of patients compared to those with-
out preserved LVSF at six month follow-up. 
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Table 5. Echocardiographic characteristics of groups of patients:  with (PLVSF M6+ group) and without (PLVSF M6– 
group) preserved global left ventricular systolic function at six months after discharge. Echocardiographic indices are 
derived from 2D, Doppler echocardiography and tissue Doppler echocardiography at hospital discharge and at six 
months after discharge, respectively
Variable PLVSF M6+ 
group (n = 70)
Hospital 
discharge
PLVSF M6+ 
group (n = 70)
After six months
PLVSF M6–  
group  
(n = 129)
Hospital 
discharge
PLVSF M6–  
group  
(n = 129)
After six months
p
PLVSF 
M6+ vs. 
PLVSF M– 
Hospital 
discharge
p
PLVSF 
M6+ vs. 
PLVSF M6– 
After six 
months
LA [mm] 38.5 (36.0–42.0) 39.0 (37.0–43.0) 40.0 (37.0–42.0) 41.0 (38.0–45.0) NS 0.04
LVEDd [mm] 48.0 (43.0–51.0) 48.0 (45.0–51.0) 49.0 (46.0–54.0) 51.0 (46.0–56.0) 0.01 < 0.001
LVEDdI [mm/m²] 25.4 (23.0–26.9) 25.9 (24.7–27.3) 25.5 (23.2–27.8) 26.5 (24.1–28.9) NS 0.006
LVESd [mm] 32.0 (29.0–35.0) 33.0 (30.0–35.0) 34.0 (31.0–38.0) 35.0 (32.0–39.0) < 0.001 < 0.001
LVESdI [mm/m²] 17.5 (15.1–18.5) 17.8 (16.0–18.6) 17.4 (16.1–19.9) 18.2 (16.4–20.2) 0.007 < 0.001
LVMI [g/m²] 105.5 (94.8–121.1) 112.7 (99.0–123.1) 120.7 (99.9–137.0) 123.1 (103.7–140.4) < 0.001 < 0.001
LVEDV [ml] 90.0 (80.0–104.0) 100.0 (88.0–117.0) 103.0 (85.0–122.0) 120.0 (94.0–146.0) < 0.001 < 0.001
LVEDVI [ml/m²] 47.5 (42.8–54.0) 55.7 (48.1–65.1) 54.0 (45.4–62.6) 61.8 (50.3–76.9) 0.002 < 0.001
LVESV [ml] 45.0 (40.0–52.0) 47.0 (40.0–55.0) 59.0 (48.0–72.0) 67.5 (51.7–84.0) < 0.001 < 0.001
LVESVI [ml/m²] 23.8 (21.7–27.7) 26.4 (23.0–30.0) 30.2 (25.4–37.7) 35.5 (27.7–43.8) < 0.001 < 0.001
LVEF [%] 50.0 (47.0–51.8) 53.0 (51.7–55.0) 42.0 (38.0–45.0) 43.2 (40,0–45.5) < 0.001 < 0.001
WMSI [pkt] 1.38 (1.31–1.44) 1.31 (1.25–1.38) 1.69 (1.44–1.81) 1.56 (1.44–1.75) < 0.001 < 0.001
DT [ms] 165.0 (150.0–190.0) 180.0 (155.0–200.0) 155.0 (145.0–185.0) 165.0 (155.0–195.0) NS 0.04
IVRT [ms] 95.0 (85.0–110.0) 105.0 (100.0–115.0) 95.0 (90.0–110.0) 105.0 (90.0–115.0) NS NS
E/A[–] 1.08 (0.79–1.5) 0.97 (0.81–1.24) 0.86 (0.72–1.23) 0.93 (0.73–1.43) NS NS
E/E’[–] 9.5 (8.1–11.2) 8.5 (7.6–10.5) 10.9 (8.6–13.2) 10.0 (8.3–12.8) 0.034 0.002
rAv [cm/s] 29.0 (26.0–32.0) 28.0 (26.0–32.0) 29.0 (27.0–33.0) 29.0 (27.0–34.0) NS 0.032
S’ [cm/s] 7.7 (6.6–8.8) 7.3 (6.4–8.0) 6.9 (6.0–7.8) 6.8 (5.8–8.2) < 0.001 0.033
S” [cm/s] 7.6 (6.8–8.9) 7.4 (6.5–8.4) 6.7 (6.0–7.9) 7.0 (5.7–8.1) < 0.001 < 0.001
Our study confirms previous evidence of the pres-
ence of a significant increase in CRP concentration in 
the course of myocardial infarction [3, 5, 20]. As report-
ed in several studies, the peak concentration of CRP 
is observed about two days from the onset of STEMI, 
then it decreases over the first week, and decreases 
further within one month, to return to normal values 
after several weeks (most often 4–6) after STEMI [1–3, 
13, 18, 19, 49–53]. Mather et al. found the decrease in 
CRP concentration in the period between one and three 
months insignificant [53]. 
Myocardial necrosis due to abrupt closure of 
coronary artery in case of acute myocardial infarction 
leads to a systemic and regional humoral and cellular 
inflammatory response [9, 54, 55]. In the early phase of 
myocardial infarction, the inflammatory response is partic-
ularly strong in the infarct region and in the border zone, 
aiming to promote the local myocardial healing process 
and scar formation [9, 54, 55]. In the beginning of acute 
STEMI, cytokines play an important cyto-protective role, 
mainly by reducing cell apoptosis [3, 56]. The process is 
facilitated by a dynamic balance between interactions in-
volving leukocytes, platelets and endothelium cells on the 
one hand, and the excretion of cytokines modulating the 
process on the other hand [3]. However, increased and 
prolonged CRP expression promotes further enhance-
ment of the necrosis area [9]. CRP binds to phospho-
choline groups of necrotic myocardial cell membranes, 
facilitating complementary activation and thus promoting 
further inflammatory response, injury of myocardial cells 
and expansion of necrosis [3, 10–13]. Literature data 
suggests that CRP should be considered an inflamma-
tory mediator holding pro-thrombotic and pro-apoptotic 
properties associated with increased apoptotic rates, 
macrophage infiltration, monocyte chemotactic protein 
expression-1 and matrix metalloproteinase-9 activity in the 
border zone [10, 12, 15, 24]. Additionally, CRP reduces 
the bioavailability of nitric oxide, which in turn suppresses 
angiogenesis and also inhibits endothelial progenitor cell 
differentiation, cellular function and survival, leading to 
further expansion of tissue injury due to ischaemia and 
reperfusion [10, 12, 15, 24]. 
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As reported in several studies, the intensity and 
sustained increase in plasma CRP concentration in 
the course of myocardial infarction may be associated 
with a greater extent of myocardial damage reflected 
by the values of cardiac necrosis markers [20, 35, 50, 
54, 57]. It is known that a strong correlation exists 
between CRP levels, infarct size, and biochemical 
markers of myocardial necrosis [20, 35, 50, 54, 57]. 
The findings by Ørn provide a potential pathophysio-
logical explanation for the association between CRP 
levels and LV remodelling, by linking peak CRP levels 
with infarct size after two months [20]. Aggepoulos 
et al. observed significantly higher baseline activity 
of troponin in patients admitted to hospital for acute 
coronary syndrome with higher levels of CRP mea-
sured within the initial 12 hours of hospitalisation [21]. 
Also in our study, which included patients with a first 
STEMI undergoing pPCI, the PLVSF M6– group ex-
hibiting a more pronounced inflammatory response, 
presented with larger infarctions as assessed by enzy-
matic assays, mainly of anterior location [17, 58–60]. 
 This is consistent with an observation by Damman et 
al., who found a higher risk of depressed LVEF at six 
months after discharge in patients with acute STEMI, 
specifically of anterior location [60]. 
In the present study, patients from the PLVSF M6+ 
group presented with a less severe inflammatory re-
sponse in the course of myocardial infarction and with 
a higher incidence of IRA and microcirculation reper-
fusion. As demonstrated by Ørn et al., individuals with 
persistent microcirculation obstruction in the course of 
STEMI present with increased CRP levels [20]. Elevated 
CRP levels during hospitalisation for STEMI have also 
been proven to correlate with persistent microcircula-
tion dysfunction and significantly poorer myocardial 
perfusion in acute anterior wall STEMI patients treated 
with pPCI [61, 62]. Also, Mayr et al. found a significant 
correlation between coronary microvascular obstruction, 
as quantified by cardiac magnetic resonance imaging 
within eight days after successful interventional reper-
fused first acute STEMI, and CRP concentration mea-
sured during the initial four days of hospitalisation [63].
The lesser severity of inflammatory reaction in the 
acute phase of STEMI, observed in the present study 
among patients with preserved LVSF in long-term 
follow-up, might be attributed to a significantly lower 
prevalence rate of DM in the study population. The 
presence of DM in patients with acute STEMI is asso-
ciated with aggravation of the systemic inflammatory 
reaction and elevation of CRP concentration [64]. Ac-
cording to the Munich Myocardial Infarction Registry, 
CRP concentration in diabetic patients is significantly 
higher from the very beginning of hospitalisation than 
in those without diabetes [65]. Also, Piestrzeniewicz 
et al. reported a higher prevalence of DM in the upper 
quartiles of admission CRP concentration in a study 
including 70 men admitted to hospital for acute STEMI 
[66]. These findings might be indicative of occurrence 
of inflammatory activation in patients with concurrent 
STEMI and DM, taking place prior to hospital admis-
sion. In a study by Suleiman et al., when comparing the 
first against the fourth quartile of CRP level at hospital 
discharge, the percentage of patients with DM was 
significantly higher in the group with CRP levels in the 
fourth quartile [40]. As demonstrated above, in the 
population of STEMI patients observed in the pres-
ent study, CRP concentration in diabetic patients, in 
contrast to those without diabetes, was continuously 
increasing from the very beginning and then throughout 
the entire hospitalisation period, reaching peak values 
at discharge, without subsequent normalisation within 
one month after STEMI [67]. These findings may sup-
port the existence of enhanced inflammatory activation 
in STEMI patients with concurrent DM, as indicated by 
other literature data [68].
Compared to the PLVSF M6– group, the course 
of the inflammatory reaction in STEMI patients with 
preserved LVSF in long-term follow-up may be 
modified by lower levels of in-hospital glycaemic 
control parameters such as admission glycaemia 
and HbA1c. Admission hyperglycaemia in STEMI 
patients has been shown to be a predictor of worse 
short- and long-term outcomes as well as with el-
evated levels of inflammatory markers [69–71]. 
As reported by Piestrzeniewicz, there was a significant 
correlation between elevated admission glycaemia 
(> 144 mg/dL) and increased CRP concentration on 
admission in a group of 70 men with acute STEMI [66]. 
The correlation between CRP concentration and the 
average 24-hour glycaemic profile measured on the 
second day of hospitalisation, reported by our team in 
a previous study, may indicate an association between 
elevated in-hospital glycaemia levels and the intensity of 
the inflammatory reaction in this group of patients [67].
Furthermore, in our study overweight and obese 
patients were more likely to present with LVEF ≤ 50% 
at six months. According to literature data, high BMI, by 
its frequent co-existence with the proinflammatory state, 
may indicate the presence of inflammatory activation 
before STEMI, in this group of patients [72–74]. 
Compared to the PLVSF M6– group, patients with 
preserved global LVSF present at six month follow-up 
showed lower BNP levels during hospitalisation. Car-
diac natriuretic peptides reflect the ventricular function 
impairment and haemodynamic decompensation in 
the course of myocardial infarction, associated with 
the size of necrotic area and intensity of inflammatory 
response [17]. According to the findings by Haeck et 
al., there is a strong relationship between BNP and 
CRP in the early phase of acute STEMI [75]. Similarly, 
in the APEX-AMI study (An Assessment of Pexelizumab 
in Acute Myocardial Infarction Substudy), including 
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5,745 patients with acute STEMI treated with pPCI, van 
Diepen et al. found significant correlations between 
interleukin-6 and CRP and BNP concentration, also in 
patients without symptoms of HF [76]. As suggested 
by these observations, the inflammatory process could 
possibly affect the expression of natriuretic peptides 
through pathways distinct from sole enhancement of 
LV wall tension. 
Significantly lower WBC24 values seen in patients 
with preserved LVSF at six months after STEMI prove 
a lower intensity of the in-hospital inflammatory re-
sponse in patients with acute coronary syndrome in this 
group of patients. Literature data suggests a significant 
correlation between WBC count, levels of myocardial 
necrosis markers, and CRP plasma concentration. 
Thus, it seems justified to regard WBC count as a prog-
nostic biomarker for predicting the size of necrotic area 
and the intensity of the inflammatory reaction in STEMI 
patients [21, 77]. Chia et al. defined the increase in WBC 
count and neutrophilia in PCI-treated STEMI patients 
as an independent predictor of MACE in long-term 
follow-up by proving their significant association with 
the infarction size and LVEF value [78]. Moreover, it has 
been demonstrated in experimental models that neutro-
penia is associated with a smaller infarction size [79].
In our study including patients with a first STEMI 
treated invasively, the prevalence of LVEF > 50% 
at discharge was estimated to be 24.0%. The more 
frequent (52% and 60%) occurrence of preserved 
LVSF before discharge reported in French registries 
USIC 2000 (Unite de Soin’s Intensifs Coronaires) and 
LVEF ≥ 50% in the MAGIC Trial (Magnesium in Coro-
naries Trial) may result from the smaller percentage of 
STEMI patients in these studies (merely 89 and 59%), 
compared to ours [26, 29]. The lower prevalence of pre-
served LVSF in pre-discharge assessment reported in 
other registries and studies may also be associated with 
the timing of the initial echocardiographic assessment, 
commonly performed in the early phase of acute STEMI 
(i.e. usually on the third day) [26, 29]. We observed 
restoration of LVEF with more frequent occurrence of 
LVEF > 50% after six months (35.4%) compared to the 
baseline values. According to data from literature, the 
prevalence of preserved LVSF in STEMI population 
is more frequent than in our study, being estimated at 
70–78% after 4-6 months from discharge. Those dis-
crepancies however may be due to more liberal criteria 
for preserved LVSF (LVEF > 40–45%) employed in other 
studies [19, 80, 81]. 
Having applied similar criteria in our study, 
LVEF > 40% was found in 80.4% of patients at six 
months after hospital discharge. There is only sparse 
long-term follow-up data available on LVSF in post-
STEMI patients treated with pPCI [80, 82–87]. Several 
researchers have reported significant improvements 
in LVSF at 3–6 months after STEMI. While van Melle 
et al. defined the LVSF improvement as an increase 
in LVEF by 6% or more, Parodi et al. used a threshold 
of ≥ 10% [80, 82]. With the latter value applied, LVSF 
improvement six months after STEMI was seen in 58% of 
patients [83]. Antoni et al. found improvement in LVSF, 
defined as a ≥ 10% decrease in global longitudinal peak 
systolic strain assessed at one year after STEMI, in 72% 
of evaluated patients [85].
The improvement in LVSF in long-term follow-up 
after STEMI depends on multiple factors, including 
myocardial stunning reversal and the size of reperfused 
myocardium, particularly in patients with anterior wall 
myocardial infarction [58, 85–90]. Concerning preser-
vation of LV function after STEMI treated with pPCI, it is 
crucial to re-establish normal blood flow in the IRA and 
achieve complete reperfusion in the coronary microcir-
culation [91]. Early achievement of optimal angiograph-
ic outcome significantly reduces the area of myocardial 
necrosis, thus allowing the preservation of LVSF after 
STEMI [32, 33, 92]. An association between impaired 
coronary microcirculation perfusion and decreased EF 
or lack of LV systolic function recovery at three months 
after pPCI-treated STEMI has already been reported in 
previous publications [93, 94]. 
In the present study, patients with preserved LVSF in 
long-term follow-up after STEMI showed a higher inci-
dence of complete myocardial reperfusion, as assessed 
by TMPG, than their counterparts from the PLVSF 
M6– group (57% vs. 40%). As suggested by literature 
data, favourable angiographic characteristics prior to 
PCI may also be beneficial in terms of LVSF preservation 
in long-term follow-up after STEMI [58, 95]. Indeed, 
as demonstrated in the present study, compared to 
their counterparts from the PLVSF M6– group, patients 
presenting with preserved global LVSF at six months 
following hospital discharge were found to have a lower 
rate of severe IRA obstruction and more frequent pres-
ervation of residual blood flow in the IRA before pPCI. 
Even modest residual flow in the IRA preceding pPCI is 
beneficial in terms of LV function recovery, possibly due 
to shortening the duration of ischaemia with resultant 
reduction in infarction size, but also due to preventing 
the ‘no reflow’ phenomenon [86, 95].
According to Parodi et al., the predictors of LVSF 
improvement in long-term follow-up in patients treated 
with pPCI for STEMI include: small enzymatic infarct 
size, short duration of time from symptom onset to 
reperfusion, mild impairment of regional LVSF in echo-
cardiographic assessment within 24 hours of hospital 
admission, and female gender [82]. Also the APEX-
TIMI trial identified infarction size as an independent 
predictor of LVEF at three months after STEMI treated 
with pPCI [94]. In a study by Hassan et al. including 
168 patients treated with pPCI for acute STEMI, peak 
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troponin level was the most important independent 
predictor of LVEF at three months after STEMI [96]. 
In the present study, patients with preserved LVSF in 
long-term follow-up after STEMI had significantly lower 
levels of myocardial necrosis markers than individuals 
from the PLVSF M6– group, both on admission and 
after the initial 24 hours of hospitalisation. Furthermore, 
the former group, in contrast to the latter, showed no 
significant regional LVSD at hospital discharge. Also, in 
patients with LVEF > 50% at discharge, the anterior wall 
location of myocardial infarction, usually associated with 
more extensive myocardial necrosis, was significantly 
less common. 
We also found lower in-hospital levels of glycaemic 
control indicators and lower prevalence of DM among 
patients with preserved global LVSF compared to 
the PLVSF M6– group. Literature data supports the 
existence of higher admission glycaemia levels in 
acute STEMI patients with a larger infarction size and 
concomitant LVSD [70, 97]. Additionally, previously we 
have reported associations between LVEF at 12 months 
after STEMI and admission levels of glycaemia and 
HbA1c [87], thus supporting the observation of other 
researchers, claiming that the co-existence of DM may 
impose a significant impact on LVSF in STEMI patients 
in long-term follow-up [98–99].
Limitations of this study
The present study has several limitations. Due to 
early achievement of reperfusion, the patients had rel-
atively well-preserved LV function. We did not account 
in our calculations for diurnal and seasonal variations in 
CRP concentration. Also, lack of concomitant assess-
ment of cytokines and growth factors are important 
limitations. Further efforts are warranted to confirm the 
clinical significance of our findings and to fully explain 
the mechanisms through which the inflammatory pro-
cess is associated with LVSF.
Conclusions
Patients with preserved global LVSF at six months 
after a first STEMI treated with pPCI have a lower inten-
sity of inflammatory response, as assessed by plasma 
CRP concentration measured during the acute phase, 
compared to patients presenting with LVEF ≤ 50% at six 
month follow-up. In patients with preserved global LVSF 
in long-term observation, CRP concentration steeply 
rises during the first 24 hours of hospitalisation, persists 
elevated until hospital discharge, and normalises within 
one month after STEMI. The lower intensity of inflamma-
tory activation in the course of STEMI in patients with 
preserved global LVSF in long-term follow-up may be as-
sociated with the following factors: smaller infarction size; 
more favourable pre-pPCI angiographic characteristics; 
better final angiographic outcome of pPCI with a higher 
rate of normal blood flow restoration in IRA and coronary 
microvascular reperfusion; milder post-infarct LV haemo-
dynamic decompensation; lower prevalence of DM; and 
lower values of admission glycaemic indices and BMI.
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